title: Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority Trial.
abstract: Homeopathy is a complementary and integrative medicine used in depression, The aim of this study is to investigate the non-inferiority and tolerability of individualized homeopathic medicines [Quinquagintamillesmial (Q-potencies)] in acute depression, using fluoxetine as active control. Ninety-one outpatients with moderate to severe depression were assigned to receive an individualized homeopathic medicine or fluoxetine 20 mg day(-1) (up to 40 mg day(-1)) in a prospective, randomized, double-blind double-dummy 8-week, single-center trial. Primary efficacy measure was the analysis of the mean change in the Montgomery & Åsberg Depression Rating Scale (MADRS) depression scores, using a non-inferiority test with margin of 1.45. Secondary efficacy outcomes were response and remission rates. Tolerability was assessed with the side effect rating scale of the Scandinavian Society of Psychopharmacology. Mean MADRS scores differences were not significant at the 4th (P = .654) and 8th weeks (P = .965) of treatment. Non-inferiority of homeopathy was indicated because the upper limit of the confidence interval (CI) for mean difference in MADRS change was less than the non-inferiority margin: mean differences (homeopathy-fluoxetine) were -3.04 (95% CI -6.95, 0.86) and -2.4 (95% CI -6.05, 0.77) at 4th and 8th week, respectively. There were no significant differences between the percentages of response or remission rates in both groups. Tolerability: there were no significant differences between the side effects rates, although a higher percentage of patients treated with fluoxetine reported troublesome side effects and there was a trend toward greater treatment interruption for adverse effects in the fluoxetine group. This study illustrates the feasibility of randomized controlled double-blind trials of homeopathy in depression and indicates the non-inferiority of individualized homeopathic Q-potencies as compared to fluoxetine in acute treatment of outpatients with moderate to severe depression.
authors.affiliation: Faculdade de Medicina de Jundiaí, Homeopathy Graduation Programme, Department of Psychobiology, Universidade Federal de São Paulo, R. Napoleão de Barros, 925 São Paulo, SP 04024-002, Brazil.
authors.forename: U C
authors.initials: UC
authors.lastname: Adler
authors.forename: N M P
authors.initials: NM
authors.lastname: Paiva
authors.forename: A T
authors.initials: AT
authors.lastname: Cesar
authors.forename: M S
authors.initials: MS
authors.lastname: Adler
authors.forename: A
authors.initials: A
authors.lastname: Molina
authors.forename: A E
authors.initials: AE
authors.lastname: Padula
authors.forename: H M
authors.initials: HM
authors.lastname: Calil
references.citation: J Clin Psychopharmacol. 2007 Apr;27(2):177-81
references.pmid: 17414242
references.citation: Br J Psychiatry. 1987 Jun;150:797-800
references.pmid: 3651734
references.citation: Acta Psychiatr Scand Suppl. 1987;334:1-100
references.pmid: 2887090
references.citation: J Consult Clin Psychol. 2006 Feb;74(1):112-20
references.pmid: 16551148
references.citation: Eur Neuropsychopharmacol. 2006 Dec;16(8):601-11
references.pmid: 16769204
references.citation: Cad Saude Publica. 2005;21 Suppl:43-53
references.pmid: 16462996
references.citation: Arch Gen Psychiatry. 1992 Aug;49(8):624-9
references.pmid: 1637252
references.citation: JAMA. 2003 Jun 18;289(23):3152-60
references.pmid: 12813121
references.citation: Pharmacol Ther. 2007 Jan;113(1):134-53
references.pmid: 17010443
references.citation: Rheumatology (Oxford). 2004 May;43(5):577-82
references.pmid: 14734789
references.citation: J Affect Disord. 2003 Sep;76(1-3):127-35
references.pmid: 12943942
references.citation: PLoS Med. 2008 Feb;5(2):e45
references.pmid: 18303940
references.citation: Pharmacopsychiatry. 2006 Mar;39(2):66-75
references.pmid: 16555167
references.citation: BMC Fam Pract. 2004 Sep 07;5:19
references.pmid: 15353006
references.citation: J Clin Psychiatry. 1999 Dec;60(12):824-30
references.pmid: 10665628
references.citation: Homeopathy. 2005 Jul;94(3):141-4
references.pmid: 16060199
references.citation: J Affect Disord. 2003 Dec;77(3):255-60
references.pmid: 14612225
references.citation: Adv Data. 2004 May 27;(343):1-19
references.pmid: 15188733
references.citation: J Clin Psychiatry. 2003 Mar;64(3):282-7
references.pmid: 12716269
references.citation: Am J Med. 2000 Jan;108(1):54-64
references.pmid: 11059441
references.citation: Expert Rev Neurother. 2006 Nov;6(11):1741-51
references.pmid: 17144787
references.citation: Br J Psychiatry. 2004 Nov;185:372-7
references.pmid: 15516544
references.citation: J Clin Epidemiol. 2008 Dec;61(12):1197-1204
references.pmid: 18834714
references.citation: J Affect Disord. 2007 Jan;97(1-3):23-35
references.pmid: 16926053
references.citation: Psychiatry Clin Neurosci. 2007 Jun;61(3):295-307
references.pmid: 17472599
references.citation: J Clin Psychopharmacol. 2002 Feb;22(1):40-5
references.pmid: 11799341
references.citation: Fam Pract. 2003 Dec;20(6):685-9
references.pmid: 14701893
references.citation: J Clin Psychiatry. 2007 Jun;68(6):935-40
references.pmid: 17592920
references.citation: Eur J Pediatr. 2005 Dec;164(12):758-67
references.pmid: 16047154
references.citation: Cad Saude Publica. 2007 Mar;23(3):565-74
references.pmid: 17334571
references.citation: Homeopathy. 2005 Jul;94(3):145-52
references.pmid: 16060200
references.citation: BMC Complement Altern Med. 2006 Nov 13;6:37
references.pmid: 17101037
references.citation: Lancet. 2005 Aug 27-Sep 2;366(9487):726-32
references.pmid: 16125589
references.citation: JAMA. 2006 Mar 8;295(10):1152-60
references.pmid: 16522836
references.citation: Homeopathy. 2005 Jul;94(3):153-63
references.pmid: 16060201